{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:09:42Z","timestamp":1788952182410,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.numecd.2026.104967","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T22:43:05Z","timestamp":1787438585000},"page":"104967","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world use of Omega-3 fatty acids: a population-based study in an Italian local health unit from Northern Italy"],"prefix":"10.1016","author":[{"given":"Andrea","family":"D'Amuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Cristini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4751-1746","authenticated-orcid":false,"given":"Sofia","family":"Tebaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Speziali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Scopa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Pagani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Santac\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Forti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Visigalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ylenia","family":"Ingrasciotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"42","key":"10.1016\/j.numecd.2026.104967_bib1","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1093\/eurheartj\/ehw334","article-title":"Cardiovascular disease in Europe: epidemiological update 2016","volume":"37","author":"Townsend","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2026.104967_bib2","series-title":"European cardiovascular disease statistics 2017","author":"Wilkins","year":"2017"},{"issue":"24","key":"10.1016\/j.numecd.2026.104967_bib3","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/eurheartj\/ehz962","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis society consensus panel","volume":"41","author":"Bor\u00e9n","year":"2020","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.numecd.2026.104967_bib4","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.numecd.2026.104967_bib5","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2026.104967_bib6","doi-asserted-by":"crossref","DOI":"10.15420\/ecr.2020.49","article-title":"The role of C-reactive protein in patient risk stratification and treatment","volume":"16","author":"Arroyo-Espliguero","year":"2021","journal-title":"Eur Cardiol"},{"issue":"7","key":"10.1016\/j.numecd.2026.104967_bib7","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/term.198","article-title":"Culture effects of epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF) on cryopreserved human adipose-derived stromal\/stem cell proliferation and adipogenesis","volume":"3","author":"Hebert","year":"2009","journal-title":"J Tissue Eng Regen Med"},{"issue":"26","key":"10.1016\/j.numecd.2026.104967_bib8","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.numecd.2026.104967_bib9","article-title":"The challenge of secondary cardiovascular prevention in very high Lipoprotein (a) level: a case report","volume":"9","author":"D'Amuri","year":"2025","journal-title":"Eur Heart J Case Rep"},{"issue":"47","key":"10.1016\/j.numecd.2026.104967_bib10","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.numecd.2026.104967_bib11","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","article-title":"The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management","volume":"2","author":"Hegele","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"22","key":"10.1016\/j.numecd.2026.104967_bib12","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose Omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.numecd.2026.104967_bib13","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.numecd.2026.104967_bib14","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"issue":"9567","key":"10.1016\/j.numecd.2026.104967_bib15","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet Br Ed"},{"issue":"1","key":"10.1016\/j.numecd.2026.104967_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"issue":"42","key":"10.1016\/j.numecd.2026.104967_bib17","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"46","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.numecd.2026.104967_bib18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1532-5415.2007.01486.x","article-title":"Statins for the primary prevention of cardiovascular events in elderly patients: a picture from clinical practice without strong evidence from clinical trials","volume":"56","author":"Trifir\u00f2","year":"2008","journal-title":"J Am Geriatr Soc"},{"issue":"7","key":"10.1016\/j.numecd.2026.104967_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102146","article-title":"Pattern of statin use in southern italian primary care: can prescription databases be used for monitoring long-term adherence to the treatment?","volume":"9","author":"Ferrajolo","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.numecd.2026.104967_bib20","series-title":"National report on medicines use in Italy. Year 2023","year":"2024"},{"issue":"1","key":"10.1016\/j.numecd.2026.104967_bib21","first-page":"111","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J 2020"},{"key":"10.1016\/j.numecd.2026.104967_bib22","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ijcard.2016.09.075","article-title":"Statin non-adherence and residual cardiovascular risk: there is need for substantial improvement","volume":"225","author":"Banach","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.numecd.2026.104967_bib23","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"13\u201314","key":"10.1016\/j.numecd.2026.104967_bib24","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00508-023-02221-4","article-title":"Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients","volume":"135","author":"Toplak","year":"2023","journal-title":"Wien Klin Wochenschr"},{"issue":"1","key":"10.1016\/j.numecd.2026.104967_bib25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2026.104967_bib26","series-title":"Rapporto OsMed 2022 \u201cL\u2019uso dei farmaci in Italia.\u201d","year":"2022"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475326004291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475326004291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:14:04Z","timestamp":1788948844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475326004291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":26,"alternative-id":["S0939475326004291"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2026.104967","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world use of Omega-3 fatty acids: a population-based study in an Italian local health unit from Northern Italy","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2026.104967","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104967"}}